Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03288948

Binocular Amblyopia Treatment

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
Retina Foundation of the Southwest · Academic / Other
Sex
All
Age
4 Years – 10 Years
Healthy volunteers
Not accepted

Summary

To evaluate the effectiveness of enhanced binocular amblyopia treatments in achieving a more complete and stable recovery.

Detailed description

To date, all studies of contrast-rebalanced binocular amblyopia treatment games used the same 10% per day contrast-increment that was designed for short-term intervention studies lasting 1-4 weeks; i.e., after 18 days of successful game play, both eyes viewed 100% contrast (no contrast-rebalancing).This study will investigate two alternative protocols designed to extend the game treatment period beyond 4 weeks to allow for more complete recovery of visual acuity. The new protocols will be compared with the original 10% contrast-increment game protocol in an 8-week 3-arm RCT to determine whether one or both of the new protocols is more effective than the current 10% increment. Based on pilot data, we expect about 40% of amblyopic children to achieve normal visual acuity in 8 weeks. In an effort to also promote recovery of binocular vision, children who attain ≤0.4 logMAR at 8 weeks will be enrolled in stereoacuity training at the 8-week visit for the next 4 weeks. Children with residual amblyopia (BCVA \>0.4 logMAR) at the 8-week visit will be provided with dichoptic movies for additional amblyopia treatment for another 4 weeks.

Conditions

Interventions

TypeNameDescription
OTHERBinocular games for treatment of amblyopiaplaying binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye

Timeline

Start date
2017-08-31
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2017-09-20
Last updated
2026-02-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03288948. Inclusion in this directory is not an endorsement.